Details for Patent: 8,636,713

Which drugs does patent 8,636,713 protect, and when does it expire?

Patent 8,636,713 protects XIPERE and is included in one NDA.

This patent has twenty-four patent family members in fourteen countries.

Summary for Patent: 8,636,713

Title:	Methods and devices for drug delivery to ocular tissue using microneedle
Abstract:	Methods and devices are provided for targeted administration of a drug to a patient's eye. In one embodiment, the method includes inserting a hollow microneedle into the sclera of the eye at an insertion site and infusing a fluid drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused fluid drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. The fluid drug formulation may flow circumferentially toward the retinochoroidal tissue, macula, and optic nerve in the posterior segment of the eye.
Inventor(s):	Prausnitz; Mark R. (Atlanta, GA), Edelhauser; Henry F. (Atlanta, GA), Patel; Samirkumar Rajnikant (Atlanta, GA)
Assignee:	Emory University (Atlanta, GA) Georgia Tech Research Corporation (Atlanta, GA)
Application Number:	13/453,407
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 8,636,713

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bausch And Lomb Inc	XIPERE	triamcinolone acetonide	SUSPENSION;INJECTION	211950-001	Oct 22, 2021		RX	Yes	Yes						TREATMENT OF MACULAR EDEMA ASSOCIATED WITH UVEITIS

International Family Members for US Patent 8,636,713

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2011248624
Australia	2015230874
Brazil	112012027416